Paul Peter Tak, CEO of Candel Therapeutics, Discusses the Treatment of Glioblastoma
By Paul Peter Tak - Last Updated: August 26, 2024Candel Therapeutics is a company which develops investigational viral immunotherapies to improve survival while maintaining optimal quality of life in patients with early- to late-stage cancer. One of its immunotherapies, CAN-3110, is a replication-competent herpes simplex virus engineered therapy which may be effective at treating patients with recurrent high-grade glioma.
Advertisement
DocWire News spoke with Paul Peter Tak, President & CEO of Candel Therapeutics, to learn more about the company, its treatment pipeline, and how CAN-3110 may offer hope to patients with glioblastoma.
Advertisement
Related Posts
Parkinson's disease and melanoma are believed to be linked due to DNA double-strand break repair thus cell proliferation.
Dr. Eric Dr. Bergson about the importance of head and neck cancer awareness, how to integrate screening into routine care.
AI analysis provides an opportunity for timely intervention to improve the ability to swallow as well as quality of life.
Euphorbis tirucalli leaf extract has the potential ability to inhibit EBV-positive cell proliferation.
A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as MARCO.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.